Key Highlights
- Bernstein maintains “outperform” rating on AZN with £186 target price, suggesting approximately 37% potential gain from £135.54 closing level
- The firm expects non-oncology products to contribute roughly 65% of AstraZeneca’s anticipated 6% compound annual growth rate from 2026 through 2031, yet the segment remains undervalued
- The broker’s 2030 sales projection of $89.06B exceeds AstraZeneca’s internal $80B target by 11% and Bloomberg’s $82B consensus by 8%
- Wainua revenue forecast for 2035 reaches $4.80B in Bernstein’s model — a 170% premium to Bloomberg’s $1.80B estimate
- Shares advanced 3.1% on June 4 to $181.80; insider transactions showed $2.2M in sales during the previous quarter with zero purchases
Shares of AstraZeneca (AZN) climbed 3.1% during trading on June 4, 2026, settling at $181.80. The pharmaceutical giant’s stock currently moves within a 52-week band spanning $134.90 to $212.71.
Bernstein released research commentary on Friday maintaining its “outperform” stance on AstraZeneca shares. The firm held steady on its £186 valuation target, compared to the £135.54 closing level — translating to potential appreciation of roughly 37%.
The central thesis is straightforward: AstraZeneca’s operations outside cancer treatments remain significantly underappreciated by the market.
According to Bernstein’s analysis, this business segment should account for approximately 65% of the pharmaceutical company’s forecasted 6% annual compound sales expansion through the 2026–2031 period. Despite this contribution, the firm notes the division continues to receive inadequate focus “in the investment debate.”
The broker projects total company revenues will reach $89.06 billion by 2030. This figure stands 11% higher than AstraZeneca’s own risk-adjusted internal projection of $80 billion and exceeds the Bloomberg consensus forecast of $82 billion by 8%. Bernstein attributes all incremental revenue versus consensus estimates from 2027 through 2035 to the non-oncology portfolio.
Wainua Represents Largest Opportunity Gap
The most significant variance appears in projections for Wainua, AstraZeneca’s treatment targeting transthyretin amyloidosis (ATTR). Bernstein’s risk-adjusted 2035 revenue model reaches $4.80 billion — representing a 170% premium over the Bloomberg consensus figure of $1.80 billion. The company’s own non-risk-adjusted peak sales guidance exceeds $5 billion.
Phase 3 CARDIO-TTransform trial results are anticipated during the latter half of 2026. Dr. Sharon Barr, AstraZeneca’s head of non-oncology research and development, observed that current U.S. diagnostic rates for ATTR cardiomyopathy remain at merely 30% — suggesting substantial room for patient population expansion.
Another compound drawing analyst attention is AZD0780, an oral PCSK9 inhibitor designed for elevated cholesterol management. AstraZeneca has set peak sales expectations above $5 billion; Bloomberg consensus currently stands at $2.40 billion. Bernstein’s 2035 projection lands at $3.10 billion.
Dr. Barr additionally highlighted that AZD0780 will not require fasting protocols — potentially offering a competitive advantage versus Merck’s rival compound enlicitide decanoate.
COPD Treatment Strengthens Investment Thesis
Tozorakimab, AstraZeneca’s chronic obstructive pulmonary disease candidate, delivered positive primary endpoint results from phase 3 trials on March 27, 2026. Company guidance places peak revenue potential between $3 billion and $5 billion, while Bloomberg consensus sits at $2 billion.
Under Bernstein’s optimistic scenario, the firm projects 179% growth potential to 2035 adjusted EBITA. The bearish case model suggests 101% downside risk.
Currently marketed products comprise 55% of the bullish valuation framework. Ultomiris leads this category, with Bernstein’s 2035 estimate of $9.60 billion substantially exceeding the consensus view of $6.50 billion.
From a valuation perspective, GuruFocus assigns AZN a GF Score of 83 out of 100. The present price-to-earnings ratio of 27.3x trades below the five-year historical median of 34.2x. The GF Value metric indicates fair value at $178.11 — marginally below the current $181.80 trading price, suggesting a minor 2.1% premium.
One area warranting attention: company insiders divested $2.2 million in shares during the preceding three-month period, with no corresponding purchase activity documented.
Phase 3 CARDIO-TTransform trial data for Wainua represents the next significant catalyst, with readout expected in the second half of 2026.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
